Viatris Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
8
Price Target
$13.50
Consensus
Outperform
Upside
10.84%
Analysts
8
Stock Rating
8
Upside
10.84%
Analysts
8
Price Target
$13.50

Viatris Stock Forecast and Price Target

The average price target for Viatris's stock of $13.50 recently provided by eight leading analysts would represent a 10.84% upside from its last closing price if reached. This potential increase is based on a high estimate of $18.00 and a low estimate of $10.00. You may be interested in rivals even if you aren't interested in Viatris stock.

$13.50

10.84% Upside

Outperform
Outperform

Viatris Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Viatris's Price has fallen from $19.09 to $15.98 – a 16.29% decrease. According to 8 prominent analysts, Viatris's Fair Value will fall by 7.03% in the next year, reaching $14.86. Over the next eight years, experts predict that Viatris's Fair Value will grow at a rate of 12.16%.

2023 Fair Value Forecast
$14.86
2024 Fair Value Forecast
$14.86
2025 Fair Value Forecast
$14.99
2026 Fair Value Forecast
$15.72
2027 Fair Value Forecast
$16.63
2028 Fair Value Forecast
$17.11
2029 Fair Value Forecast
$17.54
2030 Fair Value Forecast
$17.93
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$164.61 $181.05 9.65%
LLY Stock Forecast Eli Lilly and Outperform 16
$339.08 $333.19 17.97%
ABBV Stock Forecast AbbVie Outperform 10
$145.20 $162.12 13.64%
PFE Stock Forecast Pfizer Inc Outperform 3
$44.06 $53.97 19.50%
AZN Stock Forecast AstraZeneca PLC Outperform 8
£10.58k £153.20 -98.53%

Viatris Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Viatris's Revenue has grown by 55.53%, rising from $11.50B to $17.89B. According to 6 prominent analysts, Viatris's Revenue will fall by 7.01% in the next year, reaching $16.63B. By 2030, professionals believe that Viatris's Revenue will decrease by 4.39%, reaching $17.10B – a concerning trend for the company.

2023 Rev Forecast
$16.63B
2024 Rev Forecast
$16.51B
2025 Rev Forecast
$16.36B
2026 Rev Forecast
$17.11B
2027 Rev Forecast
$16.69B
2028 Rev Forecast
$16.82B
2029 Rev Forecast
$16.95B
2030 Rev Forecast
$17.10B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
NOVN Stock Forecast Novartis Hold 10
CHF85.77 CHF103.75 9.89%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$74.45 $80.99 11.48%
AMGN Stock Forecast Amgen Inc Hold 7
$245.17 $268.00 13.39%

Viatris Dividend per Share Forecast for 2023 - 2025 - 2030

Viatris's Dividend per Share has decreased In the last zero years, from $0.45 to $0.45 – a 0.00% drop. For next year, analysts predict Dividend per Share of $0.51, which would mean an increase of 13.33%. In 2030, professionals predict that Viatris's Dividend per Share will decrease by 100.00%, to $0.00.

2023 DPS Forecast
$0.51
2024 DPS Forecast
$0.58
2025 DPS Forecast
$0.64
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$84.50 $87.30 4.14%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$722.13 $796.73 8.29%
GSK Stock Forecast GSK Hold 16
£1.44k £16.95 -98.88%

Viatris Free Cash Flow Forecast for 2023 - 2025 - 2030

Viatris's Free Cash Flow has grown In the last two years, rising from $1.59B to $2.56B – a growth of 60.94%. In the next year, analysts believe that Free Cash Flow will reach $3.62B – an increase of 41.35%. For the next eight years, experts predict that Viatris's Free Cash Flow will grow at a rate of 61.12%.

2023 FCF Forecast
$3.62B
2024 FCF Forecast
$3.71B
2025 FCF Forecast
$3.46B
2026 FCF Forecast
$4.21B
2027 FCF Forecast
$3.69B
2028 FCF Forecast
$3.82B
2029 FCF Forecast
$4.01B
2030 FCF Forecast
$4.12B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.07k ¥0.00 35.30%
BAYN Stock Forecast Bayer Outperform 7
56.68€ 74.54€ 33.20%
RKT Stock Forecast Reckitt Benckiser Group Outperform 16
£5.81k £68.33 -98.85%

Viatris Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Viatris's Net Income has seen a drop from $16.80M to $-1.27B – a 7654.17% decrease. According to 6 major analysts, Viatris's Net Income will fall by 427.08% in the next year, reaching $4.15B. Professionals believe that By 2030, Viatris's Net Income will fall to $5.08B– a 500.13% decrease from its current value.

2023 NI Forecast
$4.15B
2024 NI Forecast
$4.18B
2025 NI Forecast
$4.22B
2026 NI Forecast
$4.43B
2027 NI Forecast
$4.70B
2028 NI Forecast
$4.83B
2029 NI Forecast
$4.96B
2030 NI Forecast
$5.08B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ALC Stock Forecast Alcon Outperform 15
CHF66.18 CHF0.00 30.51%
HZNP Stock Forecast Horizon Therapeutics Public Buy 16
$113.00 $0.00 23.89%
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.92k ¥0.00 24.74%

Viatris EBITDA Forecast for 2023 - 2025 - 2030

Viatris's EBITDA has seen impressive growth In the last two years, rising from $3.26B to $6.18B – a growth of 89.55%. According to 6 analysts, Viatris's EBITDA will fall by 3.11% in the next year, reaching $5.99B. For the next eight years, the forecast is for EBITDA to grow by 16.31%.

2023 EBITDA Forecast
$5.99B
2024 EBITDA Forecast
$5.95B
2025 EBITDA Forecast
$5.98B
2026 EBITDA Forecast
$6.28B
2027 EBITDA Forecast
$6.60B
2028 EBITDA Forecast
$6.78B
2029 EBITDA Forecast
$6.97B
2030 EBITDA Forecast
$7.19B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BAX Stock Forecast Baxter International Outperform 17
$46.68 $62.83 24.25%
FRE Stock Forecast Fresenius SE & Co. KGaA Outperform 18
27.11€ 35.72€ 19.88%
DIVISLAB Stock Forecast Divi's Laboratories Hold 18
Rp3.43k Rp5.23k 42.86%

Viatris EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Viatris's EBIT has grown by 108.66%, rising from $1.42B to $2.97B. For the next year, analysts predict that EBIT will reach $5.60B – an increase of 88.68%. Over the next eight years, experts believe that Viatris's EBIT will grow at a rate of 113.19%.

2023 EBIT Forecast
$5.60B
2024 EBIT Forecast
$5.54B
2025 EBIT Forecast
$5.53B
2026 EBIT Forecast
$5.75B
2027 EBIT Forecast
$5.98B
2028 EBIT Forecast
$6.09B
2029 EBIT Forecast
$6.21B
2030 EBIT Forecast
$6.33B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CIPLA Stock Forecast Cipla Outperform 18
Rp1.08k Rp1.05k 1.08%
JAZZ Stock Forecast Jazz Pharmaceuticals Outperform 14
$158.79 $0.00 25.95%
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 18
Rp4.27k Rp5.47k 15.97%

Viatris EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Viatris's EPS has fallen from $4.42 to $3.70 – a 16.29% decrease. According to 8 prominent analysts, Viatris's EPS will fall by 7.03% in the next year, reaching $3.44. Over the next eight years, experts predict that Viatris's EPS will grow at a rate of 12.16%.

2023 EPS Forecast
$3.44
2024 EPS Forecast
$3.44
2025 EPS Forecast
$3.47
2026 EPS Forecast
$3.64
2027 EPS Forecast
$3.85
2028 EPS Forecast
$3.96
2029 EPS Forecast
$4.06
2030 EPS Forecast
$4.15
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$56.05 $76.00 30.24%
GRF Stock Forecast Grifols Outperform 18
13.65€ 27.25€ 55.31%
PRGO Stock Forecast Perrigo Buy 16
$37.20 $47.75 27.69%